Eisai Files for Approval of Alzheimer’s Drug in Japan

Alzheimer’s drug lecanemab
10:39 JST, January 16, 2023
Japanese drugmaker Eisai Co Ltd 4523.T said on Monday it had submitted a marketing authorisation application in Japan for its Alzheimer’s drug lecanemab, which was recently granted accelerated approval in the United States.
The drug, developed in partnership with Biogen Inc BIIB.O, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease.
The company’s application is based on results from a late-stage study in which the drug was shown to reduce the rate of cognitive decline in patients with early Alzheimer’s by 27%, compared with a placebo.
"Business" POPULAR ARTICLE
-
Japan’s Nissan Motor to Cut Nearly 2,000 Jobs in U.S. Plants; Will Reduce U.S. Vehicle Production by About 25%
-
Electric Plane to Ship Cargo Between Kyushu Cities in Trial Run, in Hopes of a Greener Delivery Industry
-
Fuji Media Holdings Revises Down Its Net Profit Forecast by 66%; Advertising Revenue Projected to Plummet Following Scandal
-
Japan’s Nikkei Stock Sheds over 1,000 Points in Morning (UPDATE 1)
-
Sponsors Pull Commercials on Fuji TV after Masahiro Nakai Scandal (UPDATE 1)
JN ACCESS RANKING